These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27576543)

  • 41. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
    Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
    Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro inhibition of neutrophil elastase activity by inhaled anti-Pseudomonas antibiotics used in cystic fibrosis patients.
    Hector A; Kappler M; Griese M
    Mediators Inflamm; 2010; 2010():809591. PubMed ID: 20634941
    [TBL] [Abstract][Full Text] [Related]  

  • 43. One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis.
    Konstan MW; Flume PA; Galeva I; Wan R; Debonnett LM; Maykut RJ; Angyalosi G
    Pediatr Pulmonol; 2016 Apr; 51(4):372-8. PubMed ID: 26709158
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
    Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
    Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
    Strateva T; Petrova G; Mitov I
    J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis.
    Stanojevic S; Waters V; Mathew JL; Taylor L; Ratjen F
    J Cyst Fibros; 2014 Mar; 13(2):172-8. PubMed ID: 24091166
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
    J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis.
    Klingel M; Stanojevic S; Tullis E; Ratjen F; Waters V
    Ann Am Thorac Soc; 2019 Jul; 16(7):861-867. PubMed ID: 30874447
    [No Abstract]   [Full Text] [Related]  

  • 49. Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation.
    Price KE; Orazi G; Ruoff KL; Hebert WP; O'Toole GA; Mastoridis P
    PLoS One; 2015; 10(10):e0141192. PubMed ID: 26506004
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New clinical evidence from the European tobramycin trial in cystic fibrosis.
    Hodson ME; Gallagher CG
    J Cyst Fibros; 2002 Dec; 1(Suppl 2):199-202. PubMed ID: 15463835
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
    Woodward TC; Brown R; Sacco P; Zhang J
    J Med Econ; 2010; 13(3):492-9. PubMed ID: 20670159
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment options for cystic fibrosis: case study and panel discussion.
    Kuhn RJ; Flume PA
    Pharmacotherapy; 2002 Mar; 22(3 Pt 2):86S-87S. PubMed ID: 11898886
    [No Abstract]   [Full Text] [Related]  

  • 53. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR; Pressler T; Høiby N
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis.
    Uttley L; Harnan S; Cantrell A; Taylor C; Walshaw M; Brownlee K; Tappenden P
    Eur Respir Rev; 2013 Dec; 22(130):476-86. PubMed ID: 24293463
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis.
    Flume PA; Clancy JP; Retsch-Bogart GZ; Tullis DE; Bresnik M; Derchak PA; Lewis SA; Ramsey BW
    J Cyst Fibros; 2016 Nov; 15(6):809-815. PubMed ID: 27233377
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
    Langan KM; Kotsimbos T; Peleg AY
    Curr Opin Infect Dis; 2015 Dec; 28(6):547-56. PubMed ID: 26524327
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Proesmans M; Vermeulen F; Boulanger L; Verhaegen J; De Boeck K
    J Cyst Fibros; 2013 Jan; 12(1):29-34. PubMed ID: 22762867
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
    Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
    Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Inhaled colistin in cystic fibrosis].
    Tamm M; Eich C; Frei R; Gilgen S; Breitenbücher A; Mordasini C
    Schweiz Med Wochenschr; 2000 Sep; 130(39):1366-72. PubMed ID: 11059027
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.
    Blasi F; Carnovale V; Cimino G; Lucidi V; Salvatore D; Messore B; Bartezaghi M; Muscianisi E; Porpiglia PA;
    Respir Med; 2018 May; 138():88-94. PubMed ID: 29724399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.